Mizuho Begins Coverage on Immix Biopharma (NASDAQ:IMMX)

Equities research analysts at Mizuho began coverage on shares of Immix Biopharma (NASDAQ:IMMX) in a research note issued on Monday, Marketbeat Ratings reports. The firm set an “outperform” rating and a $14.00 price target on the stock. Mizuho’s price objective would suggest a potential upside of 108.02% from the company’s current price.

Several other equities research analysts also recently commented on IMMX. Wall Street Zen upgraded Immix Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, January 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immix Biopharma in a research note on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $11.00.

Immix Biopharma Trading Up 4.8%

NASDAQ:IMMX opened at $6.73 on Monday. The firm’s fifty day simple moving average is $5.60 and its 200 day simple moving average is $3.79. Immix Biopharma has a twelve month low of $1.34 and a twelve month high of $7.73. The firm has a market capitalization of $356.42 million, a price-to-earnings ratio of -8.74 and a beta of 0.31.

Hedge Funds Weigh In On Immix Biopharma

Several institutional investors and hedge funds have recently made changes to their positions in the business. Blue Owl Capital Holdings LP bought a new stake in shares of Immix Biopharma in the fourth quarter worth $5,158,000. Vanguard Group Inc. grew its holdings in Immix Biopharma by 4.5% during the 3rd quarter. Vanguard Group Inc. now owns 730,162 shares of the company’s stock worth $1,526,000 after acquiring an additional 31,625 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Immix Biopharma by 31.2% in the 4th quarter. Geode Capital Management LLC now owns 246,056 shares of the company’s stock worth $1,288,000 after purchasing an additional 58,580 shares during the last quarter. Goldman Sachs Group Inc. acquired a new stake in shares of Immix Biopharma in the 4th quarter valued at about $1,090,000. Finally, Susquehanna International Group LLP lifted its position in shares of Immix Biopharma by 78.8% during the third quarter. Susquehanna International Group LLP now owns 90,858 shares of the company’s stock worth $190,000 after purchasing an additional 40,032 shares during the last quarter. 11.26% of the stock is currently owned by hedge funds and other institutional investors.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.